Novo Nordisk Reports Record Profits as Demand for Weight Loss Drugs Wegovy and Ozempic Surges Amid Global Shortages and Rising Concerns over Illegal Market Sales

Novo Nordisk's record profits driven by US demand and global shortages amid rising concerns about a thriving black market and falsified versions of the weight-loss drugs, leaving the company grappling with production constraints.

Novo Nordisk reports record profits led by the US demand for weight loss drugs, Wegovy and Ozempic, amid global shortages and concerns over a black market for counterfeit versions.
With rising global shortages, a black market trade for the popular weight-loss drugs is thriving, leading to a surge in counterfeit products, endangering consumers and leading to hospitalizations over adverse reactions to fake drugs.
Novo Nordisk is grappling with production constraints due to higher-than-expected demand for its blockbuster weight-loss drugs highlighting an increasingly lucrative yet dangerously unregulated black market.
Pharmaceutical companies Novo Nordisk and Eli Lilly see record sales increase due to skyrocketing prescriptions for weight-loss and diabetes drugs, specifically Novo Nordisk's Ozempic and Wegovy.
Weight-loss drug Wegovy continues to experience supply shortages despite soaring demand and record profits, affecting the availability of the drug for new patients, particularly in the US.